InveniAI® has completed a milestone in its collaboration with PRISM BioLab.
The milestone marks completion of the identification and validation of a small molecule drug candidate against PYCARD, also known as ASC (apoptosis-associated speck-like protein containing CARD), an adaptor protein playing a key role in innate immunity and inflammatory response.